D-Pharm Ltd
REHOVOT, Israel, October 31, 2011 -
D-Pharm Ltd., (TASE: DPRM) announced today that the interim report for the DP-b99 MACSI study is expected in February, 2012.
REHOVOT, Israel, August 24, 2011 -
?
D-Pharm Ltd., (TASE: DPRM) announced today that the Korean Food & Drug Administration (KFDA) approved the Investigational New Drug (IND) application for the Phase III MACSI study of DP-b99 in Korea.
REHOVOT, Israel, July 20, 2011 -
D-Pharm Ltd., (TASE: DPRM) announced today that the Data and
Safety Monitoring Board (DSMB) for the Membrane Activated Chelator
Stroke Intervention (MACSI) study recommended that the study
continue as planned.
REHOVOT, Israel, June 14, 2011 -
D-Pharm Ltd., (TASE: DPRM) announced today publication, on-line,
in the International Journal of Stroke the protocol for its
ongoing, Phase III, Membrane Activated Chelator Stroke Intervention
(MACSI) study.
REHOVOT, Israel, May 31, 2011 -
D-Pharm Ltd.
More News
- D-Pharm Ltd Appoints CRO for Clinical Development of DP-b99 in China
- D-Pharm Receives Top-line Results From Cardiac Safety Study With DP-b99
- D-Pharm Receives Agreement Letter on Special Protocol Assessment for DP-b99 Study - a Pivotal Phase III Trial in Acute Ischemic Stroke Patients
- D-Pharm (TASE: DPRM) Announces Enrollment of First Patient in DP-b99 Phase III Efficacy Study, MACSI
- D-Pharm Enters Into Collaboration With Wanbang Biopharmaceuticals to Increase the Potential Market for its Stroke Drug-Candidate DP-b99
- D-Pharm Raises NIS 85 Million in Rights Offering and Initial Public Offering (IPO) on the Tel Aviv Stock Exchange (TASE)
- D-Pharm Submits Investigational New Drug Application and Special Protocol Assessment to the FDA for Phase III Trial of DP-b99 in Acute Stroke Patients
